Lumos Pharma(LUMO) - 2023 Q4 - Annual Results

Exhibit 99.1 Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Conference Call and Webcast Details The Company has scheduled a conference call and webcast for 4:30 p.m. ET today to discuss its financial results and ...